ASTEROID TRIAL ROSUVASTATIN PDF


Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary. The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce . statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound- Derived Coronary Atheroma Burden – ASTEROID. Mar 13, Share via: AddThis.

Author: Malarr Vule
Country: Congo
Language: English (Spanish)
Genre: Literature
Published (Last): 8 January 2006
Pages: 435
PDF File Size: 4.99 Mb
ePub File Size: 6.30 Mb
ISBN: 202-1-83899-691-4
Downloads: 23534
Price: Free* [*Free Regsitration Required]
Uploader: Nakus

A technician selected a distal branch site as the beginning point for analysis. Prior well-designed IVUS studies of statin therapy have not yielded compelling evidence for regression. Sign in to make a comment Sign in to your personal account. Change in total atheroma volume showed a rosuavstatin. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: Personnel who were unaware of the coding and were therefore blinded to the sequence subsequently analyzed both videotapes.

The current study suggests that there is potential for a more optimistic rousvastatin, in which aggressive lipid-modulating strategies can actually reverse the atherosclerotic disease process. The mean SD change in atheroma volume in the most diseased mm subsegment was Get free access to newly published articles Create a personal account or sign in to: Create a free personal account to make a comment, download free article PDFs, sign up for alerts and more.

The operator placed the IVUS catheter in the vessel originally interrogated and positioned the transducer distal to the original branch site. Mss Wolski and Goormastic are employed by the Cleveland Clinic Cardiovascular Coordinating Center, which received compensation for conducting the trial, including reimbursement for statistical services. During this pullback, images were obtained at 30 frames per second and recorded on super-VHS videotape.

Treatment to LDL-C levels below currently accepted guidelines, when accompanied by significant HDL-C increases, can regress atherosclerosis in coronary disease patients. If a patient required coronary angiography between 18 and 24 months following enrollment, an end-of-study IVUS examination was performed then, to rosuvatatin subjecting patients to an additional invasive procedure at the month visit.

  EJERCICIOS JELQ PDF

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Otherwise, P values were to be calculated using the Wilcoxon signed rank test. Because contemporary guidelines and practice patterns require intensive treatment of secondary prevention patients, randomization of patients with established coronary disease to placebo or a low-intensity statin regimen was deemed ethically unacceptable.

Baseline demographic characteristics and concomitant medications for the patients completing the trial and the patients not completing the trial are summarized in Table 1. Change in total atheroma volume showed a 6. Although statins rank among the most extensively studied therapies in contemporary medicine, the optimal target levels for low-density lipoprotein cholesterol LDL-C remain controversial.

A second imputation method assigned the 22 patients who discontinued the study because of ischemic events to a progression rate calculated from the median value for all patients completing the trial who showed progression.

The characteristics of the noncompleters were very similar to those of the completers in terms of age, sex, weight, body mass index calculated as weight in kilograms divided by the square of height in metersand prevalence of hypertension and diabetes. Rosuvastatin is the most recently introduced statin and typically produces greater reductions in LDL-C and larger increases in HDL-C than previously available agents.

After the trial was concluded and all measurements were completed, the sequence coding was unblinded to enable calculation of changes from baseline to follow-up examination.

Using this more conservative end point, only a small study of patients administered an intravenous HDL-C mimetic apolipoprotein A-1 Milano phospholipid has previously shown regression.

  LIBRETO DE LA FLAUTA MAGICA DE MOZART PDF

Nissen, Nicholls, Schoenhagen, Crowe, Tuzcu. Postmortem examination revealed a fracture of the T11 vertebral body with local muscle hemorrhage.

Treatment to LDL-C levels below currently accepted guidelines, when accompanied by significant HDL-C increases, can regress atherosclerosis in coronary disease patients. Purchase access Subscribe to the journal. Table 2 summarizes laboratory values obtained during the study for patients completing the trial.

Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion. Dr Nissen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitative arteriography: Analyses were performed using SAS software, version 8.

Table 4 demonstrates that regression occurred in virtually all subgroups, including men and women, older and younger patients, and most subgroups defined by lipid levels. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease rosuvastattin normal blood pressure: These statisticians received the trial database simultaneously with the sponsor, which included all raw data, not just derived data sets, and independently computed the IVUS efficacy parameters and confirmed the lipid level outcomes and basic demographic variables.

A total of patients had evaluable IVUS examinations at both baseline and after 24 months of treatment Figure 1.

Regression of coronary atherosclerosis by simvastatin: Coronary angiographic changes with lovastatin therapy: Analysis and interpretation of data: